PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-463

  1. 293 Posts.
    lightbulb Created with Sketch. 110
    Thanks Oxxa,Yeah that sorta makes sense, although it sounds to me like Bene are perhaps keeping their options open in case someone successfully challenges PAR's patents in a US court, or just ties them up in legal knots while a challenge (or, more accurately, a patent infringement notice from PAR), works its way through the various layers of the Federal court system. Hasn't altered my view of the positive investment case, but slightly annoyed with myself for missing this.Thanks again.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.